Free Trial

Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Bought by JPMorgan Chase & Co.

Prestige Consumer Healthcare logo with Medical background

JPMorgan Chase & Co. raised its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 3.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 272,255 shares of the company's stock after purchasing an additional 8,533 shares during the period. JPMorgan Chase & Co. owned 0.55% of Prestige Consumer Healthcare worth $19,630,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company's stock worth $30,000 after purchasing an additional 424 shares during the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC increased its holdings in shares of Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after buying an additional 400 shares during the last quarter. Huntington National Bank increased its stake in Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC grew its position in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock valued at $83,000 after acquiring an additional 1,138 shares during the last quarter. Institutional investors own 99.95% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on PBH shares. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a research report on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Tuesday. DA Davidson reaffirmed a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $85.25.

Check Out Our Latest Stock Analysis on Prestige Consumer Healthcare

Insider Buying and Selling

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business's stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares of the company's stock, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Adel Mekhail sold 9,063 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the transaction, the executive vice president now directly owns 18,365 shares of the company's stock, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock valued at $3,187,300. Corporate insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Trading Down 0.6 %

PBH stock traded down $0.42 during mid-day trading on Friday, reaching $73.96. The company had a trading volume of 330,208 shares, compared to its average volume of 319,368. Prestige Consumer Healthcare Inc. has a 12 month low of $58.22 and a 12 month high of $86.36. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The firm has a 50 day moving average of $80.56 and a 200 day moving average of $74.21. The company has a market capitalization of $3.65 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. During the same quarter in the previous year, the business posted $1.07 EPS. Prestige Consumer Healthcare's revenue was down .9% on a year-over-year basis. On average, equities analysts predict that Prestige Consumer Healthcare Inc. will post 4.44 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Company Profile

(Free Report)

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Recommended Stories

Institutional Ownership by Quarter for Prestige Consumer Healthcare (NYSE:PBH)

Should You Invest $1,000 in Prestige Consumer Healthcare Right Now?

Before you consider Prestige Consumer Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.

While Prestige Consumer Healthcare currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines